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Background
A number of macrocyclic polyamines and/or their metal
complexes are known to have anti-HIV activity. For exam-
ple, CADA compounds are triazacyclododecanes that spe-
cifically down-modulate CD4, the principal cellular
receptor for HIV. Bicyclams and their metal complexes act
as entry inhibitors by a different mechanism, via specific
binding to the cellular co-receptor CXCR4. Manganese(II)
complexes of certain penta-azacyclo-pentadecanes are
superoxide dismutase mimics and reduce oxidative stress
in cells; one such compound, M40401, has been reported
to decrease apoptosis in HIV-infected astrocytes.
Materials and methods
By synthesizing and screening various pyridine-fused
macrocyclic polyamines, we have discovered several lead
compounds that act as HIV entry inhibitors by binding to
one or both cellular HIV co-receptors, CXCR4 and CCR5.
Results
One of these new leads is SH06, the manganese(II) com-
plex of a novel ring-fused pentaazacyclopentadecane.
SH06 inhibits replication of HIV-1 IIIB and NL4.3 in MT-
4 cell cultures with IC50 values of 0.2-0.4 μg/mL and with
CC50 (cytotoxicity) of 20 μg/ml. Remarkably, SH06 inter-
acts with both HIV co-receptors CXCR4 and CCR5,
according to specific chemokine-induced calcium-signal-
ing assays. SH06 acts as an antagonist toward SDF-1-
induced Ca2+-signaling in CXCR4-transfected cells (IC50:
0.3  μg/ml) and inhibits SDF-1-induced chemotaxis of
CD4+T cells (IC50: 0.5 μg/ml). However, SH06 acts as an
agonist toward CCR5. In addition, the compound also
has significant activity (IC50: 0.8-4.9 μg/ml) against sev-
eral X4 and R5 viruses in PBMCs and monocytes/macro-
phages.
Conclusion
New macrocyclic polyamines and their manganese com-
plexes have been shown to interact with the HIV co-recep-
tors CXCR4 and CCR5 and to inhibit HIV replication in
various cell types. In particular, the manganese complex
SH06 showed promising activity against X4 HIV-1, but
also against R5 HIV-1. Analogs of this compound are of
interest as potential novel chemokine receptor inhibitors
and anti-HIV agents.
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